Market Overview - As of the close on the 18th, the Shanghai Composite Index rose by 0.5%, the Shenzhen Component Index increased by 0.37%, and the ChiNext Index gained 0.34%. The A-share market saw a trading volume of 1.59 trillion yuan, which is an increase compared to the previous day [1]. Hong Kong Market - In the Hong Kong market, the innovative drug sector showed mixed performance, while the computing power sector continued to strengthen. However, new economy stocks like Pop Mart continued to adjust. The Hang Seng Index and the Hang Seng Tech Index both rose by over 1% due to the uplift from heavyweight stocks [2]. Rare Earth Permanent Magnet Sector - On July 18, the rare earth permanent magnet sector saw renewed strength, with stocks like China Northern Rare Earth Group and Baotou Steel rising significantly. This surge was driven by the discovery of a new rare earth mineral, "Huanghoite-(Nd)", which was approved by the International Mineralogical Association. This mineral was found in the Bayan Obo deposit, the world's largest rare earth deposit, which has previously yielded over 210 mineral types. The discovery highlights the complexity and resource diversity of the deposit, and it is expected to provide new avenues for the independent development and utilization of neodymium resources, which are in high demand in sectors like electric vehicles and wind power [4]. Lithium Sector - The lithium sector experienced a significant surge, with stocks like Jinyuan Co. and Shengxin Lithium Energy hitting the daily limit. The price of lithium carbonate futures has rebounded sharply, rising from around 58,000 yuan to approximately 70,000 yuan, marking an increase of over 20%. Recent developments include regulatory actions regarding lithium resource mining, which are expected to impact supply dynamics. Analysts suggest that the current market sentiment is influenced by various factors, including policy changes and inventory levels, although concerns about resource availability persist [6]. Innovative Drug Sector - The innovative drug sector has been actively performing, with stocks like Angli Kang hitting the daily limit and reaching new historical highs. The Hong Kong market also saw significant gains in this sector, with companies like Lepu Biopharma and Akeso rising by over 20% and 10%, respectively. The National Healthcare Security Administration recently announced a new dual-track system for innovative drugs, which aims to alleviate pressure on basic medical insurance funds while meeting diverse healthcare needs [8][9].

Market Overview - Hong Kong stocks experienced a rebound with all three major indices rising over 1%, closing with the Hang Seng Index up 1.33% at 24,825.66 points and a total trading volume of HKD 238.69 billion [1] - For the week, the Hang Seng Index increased by 2.84%, the Hang Seng China Enterprises Index rose by 3.44%, and the Hang Seng Tech Index gained 5.53% [1] - The recent geopolitical tensions in the Middle East have eased, and there is a marginal improvement in US-China relations, contributing to a recovery in global market risk appetite [1] Blue Chip Performance - ZTO Express (02057) led blue-chip stocks with a rise of 6.51%, closing at HKD 152.1, contributing 6.54 points to the Hang Seng Index [2] - China Life (02628) increased by 5.13%, contributing 11.32 points, while Hansoh Pharmaceutical (03692) rose by 4.49%, contributing 2.86 points [2] - Xinyi Solar (00968) fell by 3.41%, detracting 0.75 points from the index, and Galaxy Entertainment (00027) decreased by 0.93%, detracting 1.2 points [2] Sector Highlights Stablecoin Sector - Stablecoin-related stocks saw significant gains following the US Congress's approval of the Stablecoin Innovation Act, with Yao Cai Securities Financial (01428) rising by 16.93% and Yunfeng Financial (00376) up by 15% [3] - The act aims to establish a clear legal framework for stablecoins, which is expected to enhance the compliance and development of the stablecoin industry [3] AI Sector - AI-related stocks were active, with Huya Technology (01860) rising by 15.56% and Innovation Works (02121) increasing by 10.39% [4] - The recent launch of the K2 model by Moonlight Kimi and OpenAI's ChatGPT Agent has sparked interest in AI advancements, with analysts optimistic about the sector's growth potential [4] Pharmaceutical Sector - The pharmaceutical sector showed strong performance, with Lepu Biopharma (02157) surging by 24.65% and Genscript Biotech (01672) rising by 17.97% [4] - Morgan Stanley noted a significant rebound in China's healthcare sector, with the MSCI China Healthcare Index up approximately 50% this year [5] Brokerage and Insurance Stocks - Brokerage and insurance stocks also saw gains, with GF Securities (01776) up by 5.04% and China Life (02628) increasing by 5.13% [6] - Recent policies aimed at guiding insurance funds towards long-term stable investments are expected to enhance the profitability of insurance companies [6] Notable Stock Movements - China New Economy Investment (00080) surged by 394.38% after announcing a mandatory cash offer for shares [7] - Chuangmeng Tiandi (01119) rose by 30.12% following a profit forecast indicating a turnaround [8] - Dongfang Zhenxuan (01797) increased by 12.78% due to new product launches [9] - CATL (03750) reached a new high, with Goldman Sachs projecting strong revenue and profit growth [10] - Kintor Pharmaceutical (01888) fell by 9.23% after announcing a share placement at a discount [11]

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 0.56% on July 18, with a trading volume of 2.25 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of July 17, 2024, the fund's latest share count was 2.025 billion, with a total size of 3.63 billion yuan, reflecting an increase of 412.28% in shares and 860.92% in size since December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 79.25% during the management period [2] - The top holdings of the fund include Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings such as 9.52% for Innovent Biologics and 9.47% for WuXi Biologics [2] - The fund's trading liquidity is strong, with a cumulative trading amount of 40.368 billion yuan over the last 20 trading days, averaging 2.018 billion yuan per day [1][2]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has initiated the 11th round of national drug procurement, focusing on 55 generic drugs, emphasizing quality over price, which indicates government support for industry innovation and rational competition [1][2] Group 1: Procurement Details - The procurement period is set from July 16 to July 31, during which hospitals must report their purchasing volumes [1] - The current round of procurement excludes innovative drugs and aims to optimize bidding rules to better match clinical needs and avoid excessive competition [1] - Key changes in bidding rules include allowing hospitals to report purchasing volumes by brand rather than generic names and adjusting the commitment purchasing volume based on clinical needs [1] Group 2: Impact on Major Pharmaceutical Companies - The expected sales impact on major pharmaceutical companies is limited, with estimated effects being less than 3% [1] - Specific companies and their affected products include: - Hengrui Medicine's product under JDB, contributing less than 0.5% to 2024 expected sales [2] - Hansoh Pharmaceutical's products, including Agomelatine and others, accounting for approximately 3% of 2024 expected sales [2] - CSPC Pharmaceutical's products, including Dagagliflozin and others, making up about 1% of 2024 expected sales [2] - China Biologic Products' drugs, including Olaparib and others, also representing around 1% of 2024 expected sales [2] - Shijiazhuang Yiling Pharmaceutical's products, contributing approximately 1.5% to 2024 expected sales [2] - Fosun Pharma's products, including Apalutamide, accounting for about 2% of 2024 expected sales [2]

Core Insights - The report highlights a decline in the growth rate of social consumer goods retail sales in June 2025, with a total of 4.23 trillion yuan, reflecting a year-on-year increase of 4.8%, which is below the market expectation of 5.56% [2] - The report emphasizes the promising future of COFs (Covalent Organic Frameworks) materials in various fields such as energy storage and environmental management, with a recommendation to focus on companies like Baolidi and Yaoke for their advancements in COFs commercialization [3] - The report suggests increasing allocation to the Hong Kong pharmaceutical sector, particularly in chemical pharmaceuticals and innovative drugs, highlighting companies like Sanofi and BeiGene for their potential growth [3] Retail Sector Analysis - In June 2025, the growth rate of essential goods decreased, while the jewelry sector faced demand pressure due to high gold prices, leading to a decline in growth rates [2] - The report notes that the pre-promotion period for sales has led to an earlier release of consumer demand, impacting the overall growth figures [2] COFs Industry Insights - COFs are identified as high-performance crystalline porous polymer materials with adjustable pore structures, showing significant application potential in energy and environmental sectors [3] - The report mentions a successful scale-up of COFs production by Yaoke in 2024, marking a milestone in the commercialization of these materials [3] Pharmaceutical Sector Insights - The report recommends increasing investment in the Hong Kong pharmaceutical sector, particularly in traditional and innovative drug companies, citing the ongoing transformation and innovation within the industry [3] - Specific companies are highlighted for their stable growth and potential for stock price catalysts, including Sanofi, United Laboratories, and others [3]

港股今天虽然微跌了0.08%，主要是大金融普遍调整拖累大盘，但看上去问题也不大，因为 A 股也在上 行。 黄仁勋的言论对市场影响力相当可以，其在链博会上预言，人工智能的下个浪潮是物理AI （Physic AI）—通过算法学习物理规律预测结果，替代程序员写代码，将重塑工业与机器人领域。机器人乘势 而起，优必选（09880）公布，旗下新一代工业人形机械人Walker S2 搭载全球首创人形机械人热插拔自 主换电系统，毋须人工干预或关机即可自主换电，需时仅约3分钟，令该产品具备24小时无间断工作的 能力，可避免因充电停机导致的任务中断。这个算有了一些进步，今天涨超7%。而新入品种想象力更 强，如德昌电机控股（00179）发布公告，与上海机电订立两份股权合资协议，成立两家股权式合资企 业。第一家合资公司主要作为人形机器人解决方案的销售渠道。第二家合资公司专注于人形机器人硬件 模块及系统集成的设计和制造。每家合资公司的注册资本均为7500万元人民币（约1050万美元），看来 进军机器人行业动静挺大，今天大涨超14%。其它品种地平线机器人-W(09660)涨近5%。不光是机器 人，黄仁勋基本上所有买了H20的行业都被夸了 ...

7月17日，港股创新药全天领涨，势如破竹，高纯度+高弹性标的港股通创新药ETF（520880）场内价格 一度涨近6%，收涨5.23%，全天成交额3.74亿元，环比放量超两倍，创历史天量！ 截至今日，港股通创新药ETF（520880）已连涨7日，标的指数区间累计上涨9.4%。 | | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | | | 2157 | 乐普生物-B | | 6.370 | 1.260 | 24.66% | | 2 | 2162 | 康诺亚-B | | 57.250 | 7.250 | 14.50% | | 3 | 9926 | 康方生物 | | 139.500 | 13.500 | 10.71% | | 4 | 6160 | 百济神州 | | 183.300 | 17.600 | 10.62% | | 5 | 2096 | 先声药业 | | 11.940 | 1.040 | 9.54% | | 6 | 1530 | 三生制药 | | 30.600 | 2.650 | 9.48% | | 7 ...

Core Viewpoint - The Hong Kong stock market saw a collective surge in the pharmaceutical and biotechnology sector, with notable gains in companies like Li Auto and China Biologic Products [2][4][12]. Group 1: Market Performance - The Hang Seng Index closed at 24,498.95 points, down 0.08%, while the Hang Seng Tech Index rose by 0.56% to 5,448.85 points [2]. - The total market turnover was HKD 236.4 billion, a decrease from the previous trading day, with net inflows from southbound funds amounting to HKD 1.855 billion [2]. - Among the constituent stocks, 43 rose and 40 fell, with Li Auto leading the gains at 9.73% [4]. Group 2: Notable Stock Movements - Li Auto's stock price increased by 9.73%, closing at HKD 124.10, with a year-to-date increase of 32.09% [5][19]. - China Biologic Products rose by 5.90%, with a significant year-to-date increase of 114.68% [5]. - The pharmaceutical sector saw a strong performance, with the Wande Pharmaceutical and Biotechnology Index rising by 4.65% [15]. Group 3: Sector Analysis - The healthcare sector increased by 5.17%, while the materials and energy sectors experienced declines of 1% and 0.94%, respectively [6]. - The CAR-T index rose by 8.19%, and the unprofitable biotech index increased by 6.28%, indicating strong investor interest in these areas [9]. Group 4: Regulatory Developments - The National Healthcare Security Administration and the National Health Commission introduced measures to support the high-quality development of innovative drugs, which is expected to enhance the role of commercial insurance in the multi-level medical security system [17]. - This regulatory change is anticipated to positively impact the upstream supply chain, including research reagents and CXO industries, with expected performance improvements starting from mid-2025 [17]. Group 5: Company-Specific News - Li Auto announced the opening of pre-orders for its i8 model, leading to a stock price increase of nearly 10% [18][19]. - The expected price range for the i8 is between RMB 350,000 and RMB 400,000, with the official price to be announced on July 29 [22].

Market Overview - The Hong Kong stock market showed mixed performance with the Hang Seng Index down 0.08% to 24,498.95 points and a total turnover of HKD 236.41 billion [1] - The Hang Seng Tech Index rose by 0.56% to 5,448.85 points, indicating a positive trend in technology stocks [1] - Analysts from Dongwu Overseas Strategy Team maintain a cautiously optimistic view on Hong Kong stocks, suggesting potential inflows of new capital and a focus on dividend stocks and undervalued stocks [1] Blue Chip Performance - Li Auto-W (02015) led blue-chip stocks with a 9.73% increase, closing at HKD 124.1, contributing 24.08 points to the Hang Seng Index [2] - Other notable performers included China Biologic Products (01177) up 5.9% and Hansoh Pharmaceutical (03692) up 4.39% [2] - Conversely, Chow Tai Fook (01929) and New Oriental-S (09901) saw declines of 3.55% and 2.47%, respectively, negatively impacting the index [2] Sector Highlights - The biotechnology sector was notably strong, with innovative drug stocks leading the gains, such as Lepu Biopharma-B (02157) up 24.66% and CanSino Biologics (09926) up 10.71% [3][4] - The robotics sector also showed significant activity, with companies like Delta Electronics (00179) rising 14.54% [4] - Lithium stocks experienced gains, with Ganfeng Lithium (01772) up 5% and Tianqi Lithium (09696) up 4.38% [5] Gold Market Dynamics - The gold market faced pressure as spot gold prices fell below USD 3,330, influenced by a stronger dollar and reduced safe-haven demand [7] - Gold stocks collectively declined, with Lingbao Gold (03330) down 5.2% and Shandong Gold (01787) down 3.75% [6][7] Notable Stock Movements - Changfei Optical Fiber (06869) surged 19.61% to HKD 24.4, driven by positive developments in the optical module sector [8] - Fenbi (02469) rose 18.79% following the launch of its AI-based exam preparation system [9] - Dechang Electric (00179) reached a new high with a 14.54% increase, attributed to new joint ventures aimed at enhancing its engineering capabilities [10] - China Software International (00354) increased by 12.75%, benefiting from government support for the HarmonyOS application ecosystem [11]